🇺🇸 FDA
Patent

US 11168083

Inhibitors of Plasma Kallikrein and uses thereof

granted A61PA61P7/10

Quick answer

US patent 11168083 (Inhibitors of Plasma Kallikrein and uses thereof) held by Takeda Pharmaceutical Company Limited expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P7/10